Achieving universal access to HIV treatment requires using the resources available as efficiently as possible. To this end, CHAI supports 10 countries to conduct annual resource mapping. In Malawi, results have informed the allocation of US$300 million to high-impact...
Viral hepatitis is a major public health problem throughout the world, killing more people every year than HIV.(i) Hepatitis C is a viral disease transmitted through infected bodily fluids and attacks the liver, slowly scarring the organ until the person acquires...
CHAI and global partners in the Diagnostics Access Initiative have joined with Roche Diagnostics to announce a 35 percent reduction in the price for HIV early infant diagnostic technologies. The new access price is US$9.40 per test, including proprietary reagents and...
CHAI’s Research and Development (R&D) Team works from a unique angle to support CHAI’s ambitions to improve patient outcomes in low- and middle-income countries. In particular, the team works to: 1. Identify, develop, validate, and transfer for manufacture and...
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV London, May 26, 2015 – ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access...
